Hepatitis B Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- You must have already taken part in a previous clinical trial involving a drug called imdusiran.
- You must have stopped taking a type of antiviral medication (called nucleoside analogue or NA therapy) during that previous trial, and still be off that medication.
- You must have had fewer than 3 years of follow-up check-ups since stopping that antiviral medication in the previous trial.
- You must be able to understand, agree to, and sign a consent form, and be willing to attend all required visits and follow all study rules.
Who may not be able to join:
- There are no specific exclusion criteria listed for this trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 267-332-6213
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To evaluate the durability of effect of imdusiran on HBV parameters; To evaluate the durability of effect of imdusiran on HBV parameters; To evaluate the durability of effect of imdusiran on HBV parameters
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.